Most top stocks from IBD's 33 sector groups rose Tuesday, led by biotech issues.
Alexion Pharmaceuticals (ALXN) was the biggest winner, jumping 7.03, or 6%, to 117.08 after Bloomberg reported that Swiss drugmaker Roche Holding (RHHBY) last week approached Alexion about a takeover.
The report, citing a person with knowledge of the matter, said Alexion rejected the overture but hired Goldman Sachs (GS) to help prepare for a takeover attempt.
Alexion, which develops drugs to treat rare blood disorders, briefly cleared a long, undefined pattern with resistance at around 120, before paring the gain. Volume was more than triple its daily average. It was the stock's biggest gain since July 12, after an initial report that Roche wanted to buy Alexion.
Meanwhile, Questcor Pharmaceuticals (QCOR) soared in post-session trading following a better-than-expected Q2 earnings report. The stock had hit a new high during the regular session, climbing 89 cents to 51.91 in volume that was modestly above average. It ended the session 3% above a 50.30 flat-base buy point.
Elsewhere, Evercore Partners (EVR) rose 1.43, or 3%, to a new high of 46.59. That put the investment bank 4% beyond a 44.63 buy point in an irregular consolidation.
3D Systems (DDD) suffered the biggest loss, plunging 2.36, or 5%, to 48.16 in huge volume. The maker of 3D printers said Q2 profit rose 11% to 20 cents a share, below Wall Street's forecast of 24 cents.
The stock sank below a 49.85 buy point in a late-stage cup-with-handle base after clearing the entry on Monday. On the plus side, 3D got support at its 50-day line and ended in the upper half of its trading range.
Thor 2 Trailer Administrative Professionals Day Ryan Lochte Bayern Munich the blaze Michael Shannon Chrissy Amphlett
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.